Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health
Go back to Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1183.46 +1.57 (0.13%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1181.89 | 52 Week High | $88.16 | |||
| Open | $1185.32 | 52 Week Low | $67.88 | |||
| Day High | $1190.00 | P/E | 273.95 | |||
| Day Low | $1160.84 | EPS | $4.32 | |||
| Volume | 1,924,379 | |||||
